cytarabine has been researched along with Acute Biphenotypic Leukemia in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelhafiz, A; Elfishawi, S; Gameel, A; Ibraheem, D; Kamel, A; Madney, Y; Osman, R; Radwan, E; Rasekh, EO | 1 |
| Ali, OM; Baer, MR; Duong, VH; El Chaer, F; Emadi, A; Griffiths, EA; Koka, R; Law, JY; Lee, ST; Sausville, EA; Singh, ZN; Wong, J; Yared, JA | 1 |
| Karawajew, L; Ludwig, WD; Möricke, A; Ratei, R; Schabath, R; Schrappe, M; Zimmermann, M | 1 |
| Buyukasik, Y; Goker, H; Ozcebe, OI; Sayinalp, N; Serefhanoglu, S | 1 |
| Fu, ZZ; Han, Y; He, GS; Jin, ZM; Miao, M; Qiu, HY; Sun, AN; Tang, XW; Wu, DP; Zhang, X | 1 |
| Broome, HE; Curtin, PT; Dell'Aquila, ML; Rashidi, HH; Thorson, JA; Wang, HY | 1 |
| Fan, ZP; Huang, F; Jiang, QL; Liu, QF; Meng, FY; Sun, J; Wei, YQ; Wu, MQ; Wu, XL; Xu, D; Yu, GP; Zhang, Y; Zhao, J | 1 |
| Chi, HS; Choi, SJ; Im, HJ; Jang, S; Jun, KR; Lee, JH; Lee, KH; Moon, HN; Park, CJ; Seo, JJ | 1 |
| Asakura, Y; Harano, H; Kanamori, H; Kato, K; Matuszaki, M; Mohri, H; Ogawa, K; Okubo, T; Otsuka, M; Sasaki, S; Taguchi, J; Ueda, S; Yamazaki, E | 1 |
| Arima, N; Arimura, K; Fujiwara, H; Fukumori, J; Hidaka, S; Kukita, T; Matsushita, K; Ohtsubo, H; Tanaka, H | 1 |
1 trial(s) available for cytarabine and Acute Biphenotypic Leukemia
| Article | Year |
|---|---|
Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cell Lineage; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Flow Cytometry; Humans; Immunophenotyping; Infant; Leukemia, Biphenotypic, Acute; Male; Mercaptopurine; Methotrexate; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Survival Analysis; Vincristine | 2013 |
9 other study(ies) available for cytarabine and Acute Biphenotypic Leukemia
| Article | Year |
|---|---|
Acute lymphoblastic leukemia-like treatment regimen provides better response in mixed phenotype acute leukemia: a comparative study between adults and pediatric MPAL patients.
Topics: Adolescent; Adult; Age of Onset; Aged; Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Protocols; Child; Child, Preschool; Cohort Studies; Cytarabine; Daunorubicin; Egypt; Etoposide; Female; Humans; Incidence; Induction Chemotherapy; Infant; Leukemia, Biphenotypic, Acute; Maintenance Chemotherapy; Male; Middle Aged; Phenotype; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Treatment Outcome; Young Adult | 2021 |
Treatment of CD19-positive mixed phenotype acute leukemia with blinatumomab.
Topics: Adult; Antibodies, Bispecific; Antigens, CD19; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cell Lineage; Combined Modality Therapy; Cytarabine; Dasatinib; Daunorubicin; Drug Substitution; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Leukemia, Biphenotypic, Acute; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm, Residual; Neoplastic Stem Cells; Remission Induction | 2019 |
Biphenotypic acute leukemia treated with acute myeloid leukemia regimens: a case series.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers; Case-Control Studies; Cytarabine; Female; Humans; Idarubicin; Immunophenotyping; Leukemia, Biphenotypic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Retrospective Studies | 2009 |
Outcomes of CAG regimen for refractory biphenotypic acute leukemia patients.
Topics: Aclarubicin; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Biphenotypic, Acute; Male; Remission Induction; Treatment Outcome; Young Adult | 2009 |
t(4;22)(q12;q11.2) involving presumptive platelet-derived growth factor receptor A and break cluster region in a patient with mixed phenotype acute leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Breakage; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 4; Cytarabine; Female; Flow Cytometry; Humans; Idarubicin; Imatinib Mesylate; Immunophenotyping; In Situ Hybridization, Fluorescence; Karyotype; Karyotyping; Leukemia, Biphenotypic, Acute; Middle Aged; Phenotype; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Translocation, Genetic | 2011 |
Allo-HSCT for acute leukemia of ambiguous lineage in adults: the comparison between standard conditioning and intensified conditioning regimens.
Topics: Adolescent; Adult; Busulfan; Child; Cyclophosphamide; Cytarabine; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Biphenotypic, Acute; Male; Middle Aged; Retrospective Studies; Standard of Care; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation; Young Adult | 2013 |
Relationship between in vitro chemosensitivity assessed with MTT assay and clinical outcomes in 103 patients with acute leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Child; Child, Preschool; Coloring Agents; Cytarabine; Daunorubicin; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Humans; Infant; Leukemia, Biphenotypic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tetrazolium Salts; Thiazoles; Treatment Outcome | 2007 |
[Hypoplastic mixed lineage leukemia successfully treated with low-dose cytosine arabinoside].
Topics: Antimetabolites, Antineoplastic; Cytarabine; Humans; Leukemia, Biphenotypic, Acute; Male; Middle Aged | 1996 |
Granulocyte-colony stimulating factor induces differentiation and apoptosis of CD2, CD7 positive hybrid leukemia cells in vivo and ex vivo.
Topics: Aged; Antigens, CD7; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; CD2 Antigens; Cell Differentiation; Cytarabine; DNA Fragmentation; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Biphenotypic, Acute; Lymphocyte Subsets; Male; Time Factors; Tumor Cells, Cultured | 1997 |